The abstract is read at the publisher; the summary is JClub's.
In a national cohort of 7,428 women with Hodgkin lymphoma in England and Wales, cumulative SPM incidence reached 36% by age 50, with overall invasive cancer risk elevated (SIR 3.3).
- Why it matters: Subsequent primary malignancies drive long-term treatment mortality, yet it is unclear whether modern Hodgkin lymphoma therapy has reduced these risks and how that should shape lifelong survivorship screening.
- What they did: Women diagnosed before age 36 (1954–2010) were followed through 2018 using national cancer registry linkages; standardized incidence ratios, absolute excess risks, and multivariable models assessed temporal trends and treatment associations.
- The result: Solid tumor risk decreased by 25% between 1954–1989 and 2000–2010, largely linked to reduced use, dose, and improvements in radiotherapy, but elevated risks persisted beyond 50 years, especially for lung and breast cancer.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.